Adjuvant Chemotherapy for Colon Cancer: Italian Studies

Apolone G. , Grilli R. , Alexanian A.A. , Confalonieri C. , Labianca R. , Liati P. , Marsoni S. , Martignoni G. , Mosconi P. , Nicolucci A. , Pancera G.F. , Taiana A. , Torri W. , Zaniboni A. , Liberati A. : Quality of care of colorectal cancer patients in general hospitals: diffusion and impact of management guidelines. Tumori, 76: 261–269, 1990.

ASCO. Highlights from the 32nd Annual meeting of the American Society of Clinical Oncology: Adjuvant therapy for colorectal cancer: what next? Adis publ., Suppl 4, 1996.

Buyse M. , Zeleniuch-Jacquotte A. , Chalmers T.C. : Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA, 259: 3571–3578, 1988.

Consiglio Nazionale delle Ricerche: La ricerca oncologica in Italia, Conferenza CNR P.F. Acro, sp 9, Sperimentazioni cliniche controllate nei tumori solidi, Roma 1994, 9–10 giugno: 411–453.

Francini G. , Petrioli R. , Lorenzini L. , Mancini S. , Armenio S. , Tranzini G. , Marsili S. , Aquino A. , Marzocca G. , Civitelli S. , Mariani L. , De Sando D. , Bovenga S. , Lorenzi M. : Folinic acid 5-fluorouracil as adjuvant therapy for primary colon cancer. Gastroenterology, 106: 899–906, 1994.

International Multicentre Pooled Analysis of Colon Cancer Trial (IMPACT) investigators. Efficacy of adjuvant folinic acid in colon cancer. Lancet, 345: 939–944, 1995.

Mayer R. : Chemotherapy for metastatic colorectal cancer. Cancer, 70: 1414–1424, 1992.

Moertel C.G. , Fleming T.R. , MacDonald J.S. , Haller D. , Laurie J.A. , Tangen C.M. , Ungerleider J.S. , Emerson W.A. , Tormey D.C. , Glick J.H. , Veeder M.H. , Mailliard J.A. : Fluorouracil plus levamisole after resection of stage III colon carcinoma: a final report. Ann. Int. Med., 122: 321–326, 1995.

Moertel C. , Fleming T.R. , Macdonal J.S. , Haller D.G. , Laurie J.A. , Tangen C.M. , Ungerleider J.S. , Emerson W.A. , Tormey D.C. , Glick J.H. , Veeder M.H. , Mailliard J.A. for the North Central Cancer Treatment Group, Southwest Oncology Group, and Eastern Cooperative Oncology Group: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/-Dukes’ B2 colon cancer. J. Clin. Onc., 13: 2936–2943, 1995.

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for patients with colon cancer and rectum cancer. Office of Medical Applications of Research. Bethesda, MD, National Institutes of Health, 1990, april: 16–18.

O'Connell M. , Mailliard J. , Macdonald J. , Haller D. , Mayer R. , Wieand H. : An intergroup trial of intensive course 5-FU and low-dose leucovorin as surgical adjuvant therapy for high risk colon cancer. Proc. Am. Soc. of Clin. Oncol., 12: 190, 1993.